EcoDrugPlus

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSPSMG00000010746
Gene Symbol: CCR2
1 Cross references
286 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSPSMG00000024816
Gene Symbol: CCR4
1 Cross references
254 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSPSMG00000010756
Gene Symbol: CCR5
1 Cross references
298 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSPSMG00000010683
Gene Symbol: CCR9
1 Cross references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSPSMG00000013144
Gene Symbol: CXCL8
1 Cross references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSPSMG00000024669
Gene Symbol: CXCR1
1 Cross references
158 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSPSMG00000008189
Gene Symbol: CXCR4
1 Cross references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-Type Lectin Domain Family 4 Member C

Ensembl ID : ENSPSMG00000005281
Gene Symbol: CLEC4C
1 Cross references
731 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSPSMG00000015055
Gene Symbol: CFTR
1 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Methyltransferase 1

Ensembl ID : ENSPSMG00000020383
Gene Symbol: DNMT1
1 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase I

Ensembl ID : ENSPSMG00000013733
Gene Symbol: TOP1
1 Cross references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSPSMG00000011404
Gene Symbol: TOP2A
1 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).